Meta-analysisindependent cross-checkabstract checked★ key study I-CHM-103 standard review
Chemotherapy vs supportive care alone in advanced lung cancer
Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials.
Overview
NSCLC Meta-Analyses Collaborative Group. J Clin Oncol 2008 · PMID 18678835 · DOI 10.1200/JCO.2008.17.7162
Chemotherapy raised 1-year survival from 20% to 29%.
Does the study support the specific claim? No · Methodological quality: high
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Measure survival benefit of chemotherapy in advanced lung cancer
- How was the study done?
IPD meta-analysis of randomised trials
- How many people, animals or samples were studied?
2714 patients in 16 trials
- What was actually found?
23% lower risk of death
- How large was the observed effect?
HR 0.77; 1-year survival 20% -> 29%
- What do the results mean in everyday life?
About 1 in 11 treated patients is alive at 1 year because of chemotherapy
- What are the study's limitations?
Older drugs; modest absolute gain
- What does it say about Elawady's specific claim?
Contradicts 'oncology only buys time' as meaningless and 'chemo often does not help' in fit patients
- Do the results apply to Germany and Europe?
High
- What can explicitly not be concluded from this study?
Does not show benefit for frail patients in their last weeks
Scientific in-depth review
1. Full reference
- Authors
- NSCLC Meta-Analyses Collaborative Group
- Journal
- J Clin Oncol
- Year
- 2008
- Identifier
- PMID 18678835 DOI 10.1200/JCO.2008.17.7162
- Verification
- verified – PubMed efetch 2026-10-26 (PublicationType and CommentsCorrections checked); Crossref 2026-10-26
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
Medical Research Council grants; COI not stated in abstract.
2. Research question
Does chemotherapy added to supportive care prolong survival in advanced NSCLC?
3. Study design and population
- Study design
- Meta-analysis – Systematic review and individual-patient-data meta-analysis of 16 RCTs
- Population
Patients with advanced non-small-cell lung cancer
- Country
International
- Period
Trials up to 2008
- Sample size
2714 patients, 16 RCTs
- Inclusion and exclusion criteria
RCTs of supportive care plus chemotherapy vs supportive care alone; updated IPD collected centrally
4. Methods and endpoints
- Exposure / intervention
Chemotherapy plus supportive care
- Comparator
Supportive care alone
- Endpoints
Overall survival
- Statistical methods
Pooled hazard ratios from IPD, tests for interaction by drug, regimen, subgroups
5. Actual results
- Results
HR 0.77 (95% CI 0.71-0.83), p<=0.0001; 1-year survival 20% -> 29% (absolute +9%); no clear difference by drugs or single vs combination; effect unchanged in recent trials.
- Absolute risks
1-year survival +9 percentage points (20% to 29%)
- Authors' conclusion
Chemotherapy improves overall survival in all patients with advanced NSCLC; all patients fit enough and wishing chemotherapy should receive it.
6. Strengths
- IPD, centrally checked
- Randomised comparisons
- Consistent effect across subgroups
7. Weaknesses
- Older chemotherapy regimens; most trials unblinded
- Quality of life not pooled in abstract
- Survival gain modest in absolute terms
8. Risk of bias
- Orienting tool
- AMSTAR 2
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- low
- Rationale
IPD meta-analysis of RCTs; abstract-level check.
9. Assessment of the statistical interpretation
Proportional-hazards check S1 = 0.20^0.77 = 0.29 reproduces the reported 1-year survival (stats/C-CHM-07.py); NNT about 11 for one additional 1-year survivor.
10. Relevance to the specific claim
Shows that in advanced (incurable) disease, chemotherapy given to fit patients prolongs life; limits the claim that end-of-life chemotherapy 'often does not help' to patients near death or with poor performance status.
11. Independent contrary findings
Prigerson 2015 (A-CHM-17): chemotherapy in the last months of life did not improve survival and worsened quality of death in patients with good performance status.
12. Transferability to Germany and Europe
Applicable; modern regimens (immunotherapy, targeted drugs) have larger gains.
13. Overall methodological judgement
Robust evidence of a modest survival benefit of chemotherapy in advanced NSCLC for fit patients.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | high |
| Risk of bias | low |
| Precision of results | high |
| Directness | direct |
| Reproducibility | replicated |
| Consistency with the overall evidence | consistent |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
Quality-of-life trade-offs; benefit in poor performance status.
15. Linked fact checks
- At the end of life, chemotherapy often does not help, and early palliative care improves quality of life and even survival (Temel 2010). – Studies contradicting or limiting the claim
- Oncology only buys time: 'survival rates' are meaningless, patients die during treatment, and early diagnosis only makes you 'die early'. – Studies contradicting or limiting the claim